# DOCS — Doximity, Inc.

## Company & Research Metadata

- **Company:** Doximity, Inc.
- **Ticker:** DOCS
- **Exchange:** NYSE
- **Sector / Industry:** Health Care / physician network and workflow software
- **Template version:** 2.7
- **Research date:** 2026-10-21
- **Valuation / score price snapshot:** $32.60 — 2026-11-03 regular-session close, America/New_York
- **Tracking tier:** On the Radar
- **Owned:** No
- **Primary operating period reviewed:** Q1 FY2027
- **Historical period reviewed:** TTM, FY 2026, FY 2025; latest balance-sheet date shown below
- **Latest investor presentation reviewed:** Results release and associated financial tables; no separate slide deck materially used
- **Latest earnings call reviewed:** Q1 FY2027, complete material Q&A
- **Latest post-earnings management commentary reviewed:** No separate later management presentation incorporated

- **Price snapshot date:** 2026-11-03

- **Price snapshot time / timezone:** Regular-session close, America/New_York (including exchange half-days)
- **Competitor / analyst-Q&A audit:** 2026-10-28; original operating, price and valuation snapshots retained.

## What's Changed Since Previous Review

**Current Review:** 2026-10-28

**Previous Review:** 2026-10-21

**Update Trigger:** Competitor relevance and analyst-Q&A correction

| Area | Previous View | Current View | Investment Impact |
|---|---|---|---|
| Competition | Preceding operating and comparable-company classifications | Product/customer/geographic boundaries corrected; direct rivals separated from substitutes, partners and valuation anchors | Corrects the competitive comparison; does not by itself re-underwrite the valuation |
| Analyst questions | Prior source-linked Q&A summaries | Complete questions and sentence-form management answers; all 11 existing rows retained | Improves readability while preserving the recorded exchange meaning |
| Valuation and scores | Approved operating/price snapshots, scenarios, scores and decisions | Preserved | No price refresh, rerank or change to valuation assumptions in this correction pass |

**Thesis:** No new fundamental thesis determination is made in this correction pass. The prior investment decision is preserved; the corrected competitive scope should govern the next substantive review.

## Investment Snapshot

| Metric | Current View |
|---|---|
| Price Snapshot | $32.60 — 2026-11-03 regular-session close, America/New_York |
| Rating / Zone Status | Hold / Watch |
| Bear / Base / Bull Fair Value | $9.98 / $28.83 / $55.44 |
| Scenario Probabilities | 25% / 50% / 25% |
| Probability-Weighted Fair Value | $30.77 |
| Probability-Weighted Expected Return | -5.6% |
| Bear-Case Return | -69.4% |
| Strong Buy Zone | ≤ $10.98 |
| Buy Zone | >$10.98–$24.62 |
| Avoid Chasing Above | > $34.19 |
| Quality Score / Tier | 81.3 / Tier A |
| Opportunity Score / Rank | 46.7 / #50 of 76 |
| Risk Level | Medium-High |
| Tracking / Ownership | On the Radar / Not Owned |

**Decision rationale:** DOCS is **Hold / Watch** at $33.35, with -7.7% probability-weighted upside and -70.1% bear-case return. A trusted physician audience and efficient digital distribution support attractive margins. Confidence is 58/100 because the earnings conversion, competitive and capital assumptions below remain conditional.

## Investment Thesis

A trusted physician audience and efficient digital distribution support attractive margins. Q1 FY27 revenue grew 7% to $156.6 million, while adjusted EBITDA declined and AI-related investment increased. The key question is whether new clinical tools strengthen engagement and profitable monetization enough to justify their cost. Rapid query growth is not a substitute for a sustainable revenue model.

### What the Market May Be Mispricing

| Debate | Research judgment |
|---|---|
| Physician engagement and advertiser ROI | A trusted physician audience and efficient digital distribution support attractive margins. |
| Clinical AI monetization and trust | Physician engagement, advertiser returns, campaign renewals, large-customer expansion and product costs drive value. |
| Economic margins after AI costs and SBC | Q1 adjusted EBITDA margin was 47.7%, down from 54.7%, while GAAP net margin declined more sharply. |

## Business Overview

Doximity operates a professional network and workflow tools for U.S. medical professionals. It monetizes pharmaceutical and health-system marketing, hiring and related services, while communication and clinical tools support engagement. Doximity Ask adds an AI clinical-information offering. The economic link is indirect: useful physician engagement attracts paying customers, but not every free interaction generates incremental revenue.

### Business Takeaway

Doximity operates a professional network and workflow tools for U.S. Physician engagement, advertiser returns, campaign renewals, large-customer expansion and product costs drive value.

## Industry, TAM & Market Share

Physician marketing and digital workflow remain valuable categories, but pharmaceutical budgets, privacy rules and AI competition influence growth. The size of healthcare spending is not Doximity's directly monetizable TAM. Clinical usefulness and trusted distribution matter more than broad AI-market estimates.

### Market-Share Analysis

Comparable same-definition share data for the subject and its principal rivals were not established. TAM estimates and company-specific volume measures are not treated as directly comparable market shares. The positioning analysis below is more reliable than a table of unmatched percentages.

#### Competitive Scale / Position

| Company / Platform | Primary Position | Relative Scale | Growth Direction | Investment Relevance |
|---|---|---|---|---|
| WebMD — Medscape | Direct: physician attention and pharmaceutical marketing | Product scope; no matched operating-scale series | Competes for HCP marketing budgets | Customer choice in the stated segment only |
| OpenEvidence (private) | Direct segment: clinical AI attention and HCP marketing | Product scope; no matched operating-scale series | Competes for physician engagement | Customer choice in the stated segment only |
| Sermo (private) | Segment-specific: physician community and research engagement | Product scope; no matched operating-scale series | Competes for physician attention | Customer choice in the stated segment only |
| Microsoft Teams; Zoom | Substitute segment: health-system communications | Product scope; no matched operating-scale series | Competes only in relevant workflow budgets | Customer choice in the stated segment only |

### Industry Takeaway

Clinical usefulness and trusted distribution matter more than broad AI-market estimates. The base case requires evidence of profitable adoption within that market.

## Customer Economics

Physician engagement, advertiser returns, campaign renewals, large-customer expansion and product costs drive value. Free workflow tools can lower audience acquisition costs, but AI inference and development spending must be recovered through monetization or retention. Hiring demand is cyclical.

### Customer-Economics Takeaway

The economic test is Economic margins after AI costs and SBC. Hiring demand is cyclical.

## Competitive Landscape & Moat

### Competitive Landscape

Physician marketing, recruiting and clinical workflow are distinct revenue pools. Docusign and Zeta are excluded as weak general software/marketing analogies.

| Competitor | Market Share | Positioning | Advantages vs. Company | Disadvantages vs. Company | Current Direction |
|---|---|---|---|---|---|
| WebMD — Medscape | No consistent comparable series | Direct: physician attention and pharmaceutical marketing | Established clinical content and advertiser relationships | Doximity combines a professional network with workflow tools | Competes for HCP marketing budgets |
| OpenEvidence (private) | No consistent comparable series | Direct segment: clinical AI attention and HCP marketing | Purpose-built clinical information interface | Not a full substitute for hiring and communications products | Competes for physician engagement |
| Sermo (private) | No consistent comparable series | Segment-specific: physician community and research engagement | Professional community and paid-research participation | Different workflow and monetization mix | Competes for physician attention |
| Microsoft Teams; Zoom | No consistent comparable series | Substitute segment: health-system communications | Enterprise communications distribution | Not equivalent to Doximity's physician network and marketing inventory | Competes only in relevant workflow budgets |

### Moat Assessment

Verified physician reach, professional trust and workflow integration form a strong niche advantage. Competing information services and clinical AI tools can capture attention. Maintaining accuracy, trust and privacy is essential to preserving the moat.

**Moat direction:** Stable — an analytical judgment about product and distribution economics, not a measured market-share claim.

### Competitive Takeaway

Verified physician reach, professional trust and workflow integration form a strong niche advantage. The direct rivals determine commercial pressure; diversified or sector anchors provide valuation context and are not substitutes for direct competition.

## Financial Profile

### Historical Financials

Financial reporting periods follow the issuer's fiscal year: completed FY rows plus standalone current-year quarters and cumulative H1/9M for FY2027. Revenue, FCF and SBC are flows; cash is a period-end balance. FCF = operating cash flow minus property/equipment capex from SEC company facts; quarterly FCF after Q1 and any quarterly SBC derived from YTD are visibly marked. Missing values are N/D, not zero. Unit: USD millions. Data extracted from SEC-tagged filings as of 2026-11-07. Company-specific FCF definitions and acquisition effects may require further reconciliation.

| Period | Revenue | Growth | Gross Margin | Operating Margin | FCF | FCF Margin | SBC | Diluted Shares | Cash | Debt |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| FY2025 | 570.4 | 19.98% | 90.20% | 40.46% | 273.27 | 47.91% | 72.39 | 201 | 915.66 | 12.4 |
| FY2026 | 644.86 | 13.05% | 89.09% | 34.40% | 326.46 | 50.62% | 121.63 | 199 | 748.6 | 10.19 |
| Q1 FY2027 | $156.618 | N/D | 84.9% | 21.5% | $41.925 (derived: CFO - capex) | 26.8% | $36.752 | 191.169 | $273.604 | N/D |
| Q2 FY2027 | $174.537 | N/D | 85.5% | 25.2% | $93.285 (derived: current YTD - prior YTD) | 53.4% | $40.565 (derived: current YTD - prior YTD) | 187.804 | $218.614 | N/D |
| H1 FY2027 | $331.155 | N/D | 85.2% | 23.4% | $135.21 (derived: CFO - capex) | 40.8% | $77.317 | 189.475 | $218.614 | N/D |

### Financial Takeaways

Q1 adjusted EBITDA margin was 47.7%, down from 54.7%, while GAAP net margin declined more sharply. TTM FCF of $306 million included SBC of $137 million. The valuation uses economic EPS after compensation and AI investment, rather than applying a premium multiple to unadjusted FCF.

**Financial direction:** Deteriorating — assess the reported trend alongside dilution and the balance sheet.

## Management & Capital Allocation

Management has built a profitable platform and is investing to protect relevance. Capital allocation should demonstrate that clinical AI deepens the franchise at attractive returns. Monitor paid monetization, retention and compensation intensity alongside engagement metrics.

### Management Takeaway

Monitor paid monetization, retention and compensation intensity alongside engagement metrics.

## Valuation

### Current Valuation

| Metric | Value |
|---|---|
| Price Snapshot | $32.60 — 2026-11-03 regular-session close, America/New_York |
| Market Capitalization | $5.94B |
| Enterprise Value | $5.27B |
| Trailing P/E | 39.58 |
| Provider forward P/E | 23.40 |
| EV / Sales | 8.03 |

### Comparable Company Analysis

| Company | Relevance | Public / Private | Forward P/E | EV / Sales | Growth / Margin / Risk Context |
|---|---|---|---|---|---|
| DOCS — Doximity, Inc. | Subject company | Public | 23.40 | 8.03 | physician network and workflow software; 3Y revenue-growth estimate 6.73%; operating margin 30.57% |
| Sermo; clinical AI assistants | Direct operating competitor / substitute | Unquoted / mixed operators | N/A | N/A | physician community, information and attention; no compatible standalone public multiple used |
| WebMD — Medscape | Direct: physician attention and pharmaceutical marketing | Private | N/D — no matched snapshot collected | N/D — no matched snapshot collected | Competes for HCP marketing budgets |
| OpenEvidence (private) | Direct segment: clinical AI attention and HCP marketing | Private | N/A — private | N/A — private | Competes for physician engagement |
| Microsoft Teams; Zoom | Substitute segment: health-system communications | Operating product / listed parent | N/D — no matched snapshot collected | N/D — no matched snapshot collected | Competes only in relevant workflow budgets |

**Comparable takeaway:** Physician marketing, recruiting and clinical workflow are distinct revenue pools. Docusign and Zeta are excluded as weak general software/marketing analogies. Quoted multiples retain their original dated snapshot; missing matched multiples are not estimated. Consolidated parent multiples do not isolate the competing product. No mechanical peer average is used.

The base terminal P/E is 26×, versus the provider's current forward P/E of 23.4×. Holding that quoted multiple constant on this model's 2029 EPS gives an illustrative present value of **$25.95**, versus the central base FV of **$28.83**. Earnings definitions differ, so this is a sensitivity check; it makes the dependence on a rerating or derating explicit.

### Valuation Scenarios

| Scenario | Key Assumptions | Fair Value | Probability | Probability Rationale | Return From Price Snapshot |
|---|---|---|---|---|---|
| Bear | 3Y revenue CAGR 2%; sustainable 2029 EPS $0.80 after compensation; 18× P/E; 13% discount rate; Marketing pressure and AI costs limit 2029 economic EPS to $0.80. | $9.98 | 25% | Execution, financing or competitive setbacks remain credible | -69.4% |
| Base | 3Y revenue CAGR 10%; sustainable 2029 EPS $1.60 after compensation; 26× P/E; 13% discount rate; Stable customer monetization produces $1.60 of 2029 economic EPS. | $28.83 | 50% | Most likely operating trajectory, requiring measurable progress | -11.6% |
| Bull | 3Y revenue CAGR 18%; sustainable 2029 EPS $2.50 after compensation; 32× P/E; 13% discount rate; Strong AI-supported engagement and paid adoption produce $2.50 of 2029 economic EPS. | $55.44 | 25% | Successful product conversion and operating leverage; not assured | +70.1% |
| **Probability-Weighted** | Sum of each scenario value × its probability | $30.77 | **100%** | Judgmental scenario probabilities | -5.6% |

### Valuation Takeaway

- **Primary valuation method:** Present value of sustainable 2029 equity earnings × scenario P/E, plus assumed interim dividends. The three-year discount horizon approximates late-2029 earning power.
- **Cross-check methods:** Direct competition, quoted peer multiples, current cash conversion, and the separate revenue/share/net-margin bridge in [the valuation workpaper](../valuation/watchlist_models_2026-10-21.md).
- **Key valuation dependencies:** Physician engagement and advertiser ROI; Clinical AI monetization and trust; Economic margins after AI costs and SBC. All forward figures are independent research assumptions, not company guidance or consensus.
- **Valuation confidence / Risk Level:** 58/100 / Medium-High. Scenario values are sensitive to sustainable earnings and terminal multiples.
- **Margin-of-safety conclusion:** Hold / Watch at $33.35. New-file boundaries use Strong Buy = min(P/W FV ÷ 1.5, 1.1 × bear FV), Buy upper = P/W FV ÷ 1.25, Avoid above = P/W FV ÷ 0.90. Returns are to present fair value, not annualized returns or price targets for a particular date.

## Analyst Questions

The table consolidates related questions and follow-ups from each material participant in the complete call.

| Analyst / Firm | Core Question | Management Response | Research Read-Through |
|---|---|---|---|
| Brian Peterson / Raymond James | What evidence supports the clinical AI opportunity, and how mature is monetization? | Management described encouraging evidence but said the monetization ramp remains early. | Value the opportunity only as permissions and evidence mature. |
| Craig Hettenbach / Morgan Stanley | Does AI search generate enough revenue to cover its serving cost? | Management said search revenue exceeds serving cost. | Confirm that this opportunity converts into profitable recurring demand. |
| Michael Cherny / Leerink Partners | How does the broader AI strategy reach enterprise customers? | Management said existing enterprise relationships support distribution. | Confirm that this opportunity converts into profitable recurring demand. |
| Ryan Daniels / Blair | What is driving sales demand for the new offerings? | Management said new buying categories are generating customer requests. | Confirm that this opportunity converts into profitable recurring demand. |
| Ryan MacDonald / Needham & Company | How do health-system requirements and privacy affect the offering? | Management said enterprise security remains a source of differentiation. | Confirm that this opportunity converts into profitable recurring demand. |
| Elizabeth Anderson / Evercore ISI | How much of pharmaceutical budgets is currently allocated to AI? | Management said AI spending remains a small share of those budgets. | Confirm that this opportunity converts into profitable recurring demand. |
| Steven Valiquette / Mizuho Securities | Has the outlook for the healthcare marketing recovery changed? | Management said its broad market assumptions are unchanged. | Treat the stated timetable as conditional on demonstrated execution. |
| Jessica Tassan / Piper Sandler | How does the buyer mix for AI products expand the opportunity? | Management said clinical content broadens the opportunity. | Stress monetization if competition or mix reduces economic yield. |
| Sean Dodge / BMO Capital Markets | How do agency relationships help reach pharmaceutical customers? | Management said agency partnerships improve reach. | Confirm that this opportunity converts into profitable recurring demand. |
| Alexei Gogolev / JPMorgan | Can customers buy search together with core marketing campaigns? | Management said search and core campaigns can be packaged together. | Confirm that this opportunity converts into profitable recurring demand. |
| Scott Schoenhaus / KeyBanc | How is the purchasing cadence for new AI offerings developing? | Management said future purchasing formats are still evolving. | Confirm that this opportunity converts into profitable recurring demand. |

### Analyst-Q&A Takeaway

AI engagement creates new monetization options, but product revenue is early and marketing-market growth remains modest. Search economics need to offset investment costs without relying on a rapid budget shift.

## Thesis Monitoring

| Driver | Current State | Positive Trigger / Catalyst | Negative Trigger / Falsifier | What It Changes |
|---|---|---|---|---|
| Physician engagement and advertiser ROI | A trusted physician audience and efficient digital distribution support attractive margins. | Revenue trajectory sustains approximately 10% annual growth on a comparable basis | Growth remains below the 2% bear assumption over a full operating cycle | Revenue outlook and scenario probabilities |
| Clinical AI monetization and trust | Physician engagement, advertiser returns, campaign renewals, large-customer expansion and product costs drive value. | After-cost earnings progress toward the base implied net margin of 32.2% | Competition, credit losses or service costs make that margin trajectory unattainable | Margins, moat score and valuation multiple |
| Economic margins after AI costs and SBC | Q1 adjusted EBITDA margin was 47.7%, down from 54.7%, while GAAP net margin declined more sharply. | Financing and compensation remain consistent with 175.6M economic shares in the 2029 base case | Required capital or cumulative dilution materially exceeds the model without matching earnings | Financial score, confidence and downside value |

## Quality & Opportunity Scorecards

### Quality Score

| Component | Score | Weight | Weighted Contribution | Evidence |
|---|---|---|---|---|
| Business durability and economics | 84 | 25% | 21.0 | Physician engagement, advertiser returns, campaign renewals, large-customer expansion and product costs drive value. |
| Moat and competitive position | 85 | 25% | 21.3 | Verified physician reach, professional trust and workflow integration form a strong niche advantage. |
| Growth runway and durability | 76 | 20% | 15.2 | Physician marketing and digital workflow remain valuable categories, but pharmaceutical budgets, privacy rules and AI competition influence growth. |
| Financial quality and balance sheet | 83 | 15% | 12.5 | Q1 adjusted EBITDA margin was 47.7%, down from 54.7%, while GAAP net margin declined more sharply. |
| Management, governance and capital allocation | 76 | 15% | 11.4 | Management has built a profitable platform and is investing to protect relevance. |
| **Quality Score** | **81.3** | **100%** | **81.3** | Weighted score, independent of ownership and current price |

- **Quality Tier:** A
- **Speculative override:** None

### Opportunity Score

| Component | Raw Input | Normalized Score | Weight | Weighted Contribution |
|---|---|---|---|---|
| Quality | 81.3 | 81.3 | 30% | 24.4 |
| Probability-weighted upside | -5.6% | 38.8 | 35% | 13.6 |
| Bear-case downside | -69.4% | 0.0 | 20% | 0.0 |
| Risk / valuation confidence | 58 | 58.0 | 15% | 8.7 |
| **Opportunity Score** |  | **46.7** | **100%** | **46.7** |

- **Opportunity Rank:** #50 of 76
- **Zone Status:** Hold / Watch

## Portfolio Context

- **Tracking tier:** On the Radar
- **Owned:** No
- **Tracking source of truth:** `ontheradar.md`
- **Portfolio source of truth:** `portfolio/holdings.md`
- **Scoring independence:** Ownership, account, shares, position size and cost basis do not change research, valuation, Quality, Opportunity, rank or zones.

## Investment Decision History

| Timestamp | Price | Rating | Zone Status | Buy Zone | Strong Buy Zone | Avoid Chasing Above | Base FV | P/W FV | P/W Return | Quality | Opportunity / Rank | Change / Rationale |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-21 (America/New_York) | $33.35 | Hold / Watch | Hold / Watch | >$10.98–$24.62 | ≤ $10.98 | > $34.19 | $28.83 | $30.77 | -7.7% | 81.3 | 45.2 / #43 | Initial missing-file analysis; common-universe ranking; independent scenario assumptions |

---

## Material Sources

| Source | Type | Date / Period | What It Supports |
|---|---|---|---|
| [Doximity - Doximity Announces Fiscal 2027 First Quarter Financial Results](https://investors.doximity.com/news/news-details/2026/Doximity-Announces-Fiscal-2027-First-Quarter-Financial-Results/default.aspx) | Company IR / earnings filing | Q1 FY2027 | Latest operating results, guidance, products and financial supplement |
| [DOCS complete earnings-call transcript](https://stockanalysis.com/stocks/docs/transcripts/668286-q1-2027/) | Transcript | Q1 FY2027 | Prepared remarks and all material Q&A exchanges |
| [DOCS regular-session historical price](https://stockanalysis.com/stocks/docs/history/) | Market data | 2026-10-20 close | Common price used in returns, scores and zones |
| [DOCS valuation statistics](https://stockanalysis.com/stocks/docs/statistics/) | Market data | 2026-10-20 close; ratios retrieved 2026-10-21 | Market capitalization, shares, quoted multiples and current ratios |
| [DOCS historical income statement](https://stockanalysis.com/stocks/docs/financials/income-statement/) | Standardized financial statements | Latest reported period and two preceding fiscal years | Historical income statement; source-native currency and definitions |
| [DOCS historical balance sheet](https://stockanalysis.com/stocks/docs/financials/balance-sheet/) | Standardized financial statements | Latest reported period and two preceding fiscal years | Historical balance sheet; source-native currency and definitions |
| [DOCS historical cash flows](https://stockanalysis.com/stocks/docs/financials/cash-flow-statement/) | Standardized financial statements | Latest reported period and two preceding fiscal years | Historical cash flows; source-native currency and definitions |
| [Zeta Global Holdings Corp. statistics](https://stockanalysis.com/stocks/zeta/statistics/) | Comparable-company market data | 2026-10-20 regular close | Peer multiples and financial context; public quote basis |
| [FY2026 10-K — member, marketing and workflow competition](https://www.sec.gov/Archives/edgar/data/1516513/000151651326000025/docs-20260331.htm) | Regulatory filing / primary product evidence | FY ended 2026-03-31; checked 2026-10-28 | Medscape, OpenEvidence and communications competitors by budget |
| [Sermo — community and medical research offering](https://support.sermo.com/hc/en-us/articles/15550464371099-About-Sermo) | Regulatory filing / primary product evidence | Current product description; checked 2026-10-28 | Physician-community overlap; distinct research economics |
| [SEC XBRL company facts — DOCS](https://data.sec.gov/api/xbrl/companyfacts/CIK0001516513.json) | Regulatory filing (as tagged) | FY2027, through 2026-09-30 | Current-year standalone-quarter and year-to-date source facts for FCF, SBC, revenue and other reported metrics |